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Introduction: The burden of stroke on the community is growing, and therefore, so is the
need for a therapy to overcome the disability following stroke. Cellular-based therapies
are being actively investigated at a pre-clinical and clinical level. Studies have reported
the beneficial effects of exogenous stem cell implantation, however, these benefits are
also associated with limited survival of implanted stem cells. This exploratory study
investigated the use of transcranial magnetic stimulation (TMS) as a complementary
therapy to increase stem cell survival following implantation of human dental pulp stem
cells (DPSC) in the rodent cortex.
Methods: Sprague-Dawley rats were anesthetized and injected with 6 × 105 DPSC
or control media via an intracranial injection, and then received real TMS (TMS0.2 Hz)
or sham TMS (TMSsham) every 2nd day beginning on day 3 post DPSC injection for
2 weeks. Brain sections were analyzed for the survival, migration and differentiation
characteristics of the implanted cells.
Results: In animals treated with DPSC and TMS0.2 Hz there were significantly less
implanted DPSC and those that survived remained in the original cerebral hemisphere
compared to animals that received TMSsham. The surviving implanted DPSC in TMS0.2 Hz
were also found to express the apoptotic marker Caspase-3.
Conclusions: We suggest that TMS at this intensity may cause an increase in
glutamate levels, which promotes an unfavorable environment for stem cell implantation,
proliferation and differentiation. It should be noted that only one paradigm of TMS was
tested as this was conducted as a exploratory study, and further TMS paradigms should
be investigated in the future.
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INTRODUCTION
Stroke is a leading cause of long-term severe disability (Truelsen et al., 2007), resulting in
persistent neurological deficits and profound physical deconditioning that propagates disability
and worsens cardiovascular risk (Ivey et al., 2006). Indeed, nearly half of all older stroke
survivors experience ongoing moderate to severe disability. Consequently, there is a pressing
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need for the development of novel and effective therapies. One of
the most promising approaches is exogenous stem cell therapy,
which involves the implantation of a stem cell source from
outside of the brain. Human dental pulp stem cells (DPSC)
are an attractive option for exogenous stem cell therapy (Leong
et al., 2012) and have many advantages as a potential cell based
therapy for stroke. Firstly, teeth provide a clinically accessible
source of human adult stem cells. Secondly, human DPSC
when exposed to the appropriate environment have neurogenic
potential, generate electrophysiologically functional neurons and
can influence a host’s nervous system to alter connectivity
(Arthur et al., 2008). Thirdly, ex vivo human DPSC have a
high proliferative capacity that can generate sufficient cells
for future human stem cell therapy (Gronthos et al., 2000)
and fourthly, due to improved dental hygiene, many older
adults possess their own teeth which could then be used to
generate their own human DPSC for autologous transplantation.
The mechanism of action of cell-based therapies including
human DPSC transplantation, is likely through a variety of
actions including direct cell replacement, immunomodulation,
neuroprotection, angiogenesis and neuroplasticity (Leong et al.,
2012).
There are currently many obstacles to overcome when using
exogenous stem cell therapy. One such problem is the limited
survival, differentiation and connectivity of DPSC implants. It
has been reported that as few as 2.3% of implanted human
DPSC survived following intracerebral transplantation of human
DPSC into the rodent brain (Leong et al., 2012). Despite the
low survival rate of implanted DPSC, significant functional
improvement was seen in animals that received the DPSC
compared to vehicle only controls (Leong et al., 2012). This
highlights the exciting potential for stem cell therapy to improve
functional outcomes following stroke. However, a combination
of therapies which promote stem cell survival, differentiation and
the development of appropriate connectivity between implanted
cells and the local neuronal population may be necessary to
provide the optimum outcome. Mounting evidence indicates
that a major cause of limited survival of transplanted cells is
due to a lack of sufficient growth factors at the transplant
site (Wang et al., 2013). The deficiency in trophic support in
the post stroke brain is the result of the pathophysiological
cascade following an occluded blood vessel and disrupted
cerebral blood flow. This cascade generates a number of events,
including increased apoptosis due to elevated Ca2+, impaired
mitochondrial function, energy depletion and excitotoxicity
caused by the uncontrolled release of glutamate, all making the
brain a hostile environment (Durukan and Tatlisumak, 2007).
These factors not only prevent proliferation and survival of
implanted stem cells, but also the surviving endogenous cells,
as regeneration of endogenous neurons in the infarct area is
minimal (Wang et al., 2013).
Transcranial Magnetic Stimulation (TMS) is one technique
that may be useful in optimizing conditions for stem cell
survival. TMS was developed as a non-invasive and well
tolerated method for the focal stimulation of human cortical
areas and has been used in both research and clinical settings
(Rothwell, 1997). There is indirect evidence from both human
and animal studies that have indicated that TMS can provide
an environment which may prove beneficial for stem cell
survival. Recent studies have also demonstrated that TMS
increases endogenous neurotrophins in rodents brains such
as glutamate and brain-derived neurotrophic factor (BDNF)
which are both known to induce signaling pathways that lead
to neurogenesis (Ikonomidou and Turski, 2002; Ma et al.,
2013; Tan et al., 2013). Low frequency magnetic stimulation
has been proposed to increase neurotrophic factors BDNF
and neurotrophic growth factor (NGF; Tan et al., 2013)
which are factors known to be beneficial for stem cell
growth and survivial (Bates and Rodger, 2015). As exogenous
neurotrophins are unable to penetrate the blood brain barrier,
TMS application is a feasible, cost effective and well tolerated
method to non-invasively increase neurotrophin content in
the brain, eliminating the risk of increasing intracranial
pressure and traumatic brain injury if these factors were to
be intracerebrally injected (Tan et al., 2013). TMS has also
recently been translated from humans to a variety of animal
models including rats and cats to examine cortical changes in
animal disease models in order to investigate the underlying
physiology of common TMS phenomena (Funke and Benali,
2010, 2011).
Therefore the aim of this exploratory pilot study is to identify
a novel approach using a combination of TMS therapy following
stem cell injection in the mammalian brain that will optimize
conditions within the brain for stem cell survival and the
development of appropriate connectivity. We hypothesize that
repeated periods of TMS following DPSC transplantation will
produce changes within the cortex that are beneficial for stem
cell survival and differentiation.
MATERIALS AND METHODS
Animal and Experimental Preparation
Experiments were carried out on Sprague-Dawley rats, male,
weighing 300 g (University of Adelaide, Laboratory Animal
Services). A total of 26 rats were used in this study. The animals
were maintained on a 12 h light/dark cycle with ad libitum access
to food and water. All experimental procedures complied with
the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes and were used with permission from
the University of Adelaide Animal Ethics Committee (approval
number M-2011-108).
Dental Pulp Stem Cell Culture and
Preparation
Human DPSC were previously isolated from adult impacted
third molars by digestion of pulp tissue (Arthur et al., 2008) and
characterized (Gronthos et al., 2002) and retrovirally transduced
to express green fluorescent protein (GFP; Arthur et al., 2009).
Human Ethics for DPSC isolation was obtained from The
University of Adelaide H-73–2003. DPSC at passages 5–7 were
cryopreserved in 10% dimethyl sulfoxide in fetal calf serum. Cells
were thawed and passaged at least one time prior to use for
intracerebral transplantation. DPSC were cultured as previously
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described [4], in α-modified Eagle’s medium (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 10% fetal calf serum,
100 µM L-ascorbic acid 2-phosphate (Wako, Richmond, VA,
USA), 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL
streptomycin at 37◦C in 5% CO2. Cells were dissociated with
trypsin and resuspended in α-modified Eagle’s medium without
supplements at a concentration of 1.5 × 105 cells/µL. Cell
viability was determined using the trypan blue exclusionmethod.
Dental Pulp Stem Cell Injection
Prior to surgery all animals were housed in an animal care facility
for at least a week. Animals were anesthetized with isoflurane and
1.5 L/min oxygen (3% induction, 1.5–2%maintenance). Animals
were randomly selected to receive human DPSC (6 × 105 cells
in 4 µL total volume) or a media only injection. The injection
of cell suspension or media was made into the right hemisphere
parenchyma at two stereotaxic coordinates (anterior-posterior,
medial-lateral relative to bregma; dorsal-ventral from dura): 2µL
into the striatum (−0.40, +4.00; −5.50 mm) and another 2 µL
into the cortex (−1.40, +4.00, −1.75 mm) using a stereotaxic
frame (Kopf instruments, Tujunga, CA, USA).
Transcranial Magnetic Stimulation of the
Mammalian Brain
Following surgery animals recovered for 48 h and then received
TMS on days 3, 5, 8, 10 and 12 post surgery (Figure 1). Animals
injected with DPSC were randomized to receive real stimulation
(TMS0.2 Hz) or sham TMS stimulation (TMSSham). Animals
injected with control media received TMS0.2 Hz. During TMS
application animals were anesthetized using a mixture of Xylazil
(4 mg/kg) and Ketamine (30 mg/kg). TMS0.2 Hz was applied with
a round coil (external diameter 13 cm; Magstim 200 (Magstim
Co., Dyfed, UK)) connected to a monophasic stimulator with
the center of the coil placed over the vertex with the handle
pointing posteriorly. The coil was placed so that the coil current
flowed in a clockwise direction so the right hemisphere was
preferentially stimulated (see Figure 1). TMS was administered
using 60% maximal stimulator output for 15 min at 0.2 Hz.
This was the maximum intensity that could be applied at 0.2 Hz
for 15 min without the coil overheating (determined in pilot
studies). This intensity of resulted in a motor response in all the
anesthetized animals (hind limb motor response was seen in all
animals). Sham stimulation was administered by tilting the coil
90◦. There was no direct stimulation of the rat brain during sham
stimulation.
Immunohistochemistry and Imaging
Two days following the final post-surgical TMS session rats were
deeply anesthetized (5% isoflurane) and transcardially perfused
with ice-cold saline followed by 4% (w/v) paraformaldehyde
in phosphate-buffered saline. Brains were removed and post-
fixed in the same fixative at 4◦C overnight. Following fixation,
brains were cryoprotected with 30% sucrose and embedded in
optimum cutting temperature compound. Serial coronal sections
of 8–12 µm were taken through the brain tissue surrounding the
injection site.
Double immunohistochemistry studies were performed
by blocking sections with 10% normal donkey serum in
phosphate-buffered saline containing 0.3% Triton X-100, before
DPSC were identified using goat anti-GFP (1:250; Rockland,
Gilbertsville, PA, USA1). An antibody against Nestin was used
for identification of neural stem cells (mouse anti-nestin; 1:100;
Abcam, Cambridge, U.K.2), and cell death via Caspase-3 pathway
was investigated with Cleaved Caspase-3 (1:1600; Cell Signaling
Technology3). Other primary antibodies used were mouse anti-
neuronal nuclei (NeuN) for mature neurons (1:500, Millipore),
rabbit anti-glial fibrillary acidic protein (GFAP) to stain for
astrocytes (1:250, DAKO, Glostrup, Denmark) and mouse anti-
β-III Tubulin (1:500, Millipore). Secondary antibodies were
either alexa fluor 488-conjugated anti-goat IgG, 568-conjugated
anti-rabbit IgG or 647-conjugated anti-mouse IgG (1:200,
Molecular Probes, Invitrogen Carlsbad, CA, USA4). Antibodies
were diluted in blocking solution. All sections were mounted
with ProLong Gold Antifade with DAPI reagent (Invitrogen,
Carlsbad, CA, USA4). No primary antibody and no secondary
antibody controls were used in triplicate to ensure accuracy of
staining. Images were taken using Zeiss Axioscope microscope
with Axiocam MRm high-resolution camera and Axiovision
4.8.1 imaging Software. DPSC numbers were determined by
counting the numbers of GFP positive cells in five brain areas
(Figure 2A) in up to 13 serial brain sections taken from four
different rats in each treatment group.
In Vitro Glutamate Activity Assay
Human DPSC were plated at a density of 5 × 104 cells / well in
100µL of DPSC cell culture medium in a 96 well plate. Cells were
allowed to adhere for 3 h under standard culture conditions. At
3 h post-plating, cells were incubated with various concentrations
of Glutamate (Sigma, G1251) for either 15 min to simulate the
up-regulation of glutamate seen during TMS, 24 h or one trial
where glutamate was added for 15 min, followed by a washout
step for 45 min with the addition of glutamate and washout was
repeated for a total of six times to replicate the in vivo paradigm of
TMS used with each experiment completed in triplicate. Twenty-
four hours after cells were initially plated, 10 µL of WST-1 cell
proliferation reagent (Scientifix, Cheltenham, VIC, Australia)
was added and cell proliferation was read at 450 nm and 690 nm.
Statistics
GraphPad Prism (version 6.01) Software was used to perform a
student’s t-test or one-way ANOVA, as appropriate.
RESULTS
Number of DPSC were Decreased in TMS
Treated Rat Brains
Five areas of the brain were analyzed and counted for GFP
expressing DPSC (Figure 2A). This part of the study compared
1www.rockland-inc.com
2www.abcam.com
3www.cellsignal.com
4www.invitrogen.com
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FIGURE 1 | Experimental design. (A) Diagramatic representation of the transcranial magnetic stimulation (TMS) coil position in relation to rat position.
(B) Experimental timeline including dental pulp stem cells (DPSC) injection and TMS treatments.
FIGURE 2 | Human dental pulp stem cell (huDPSC) numbers are decreased in animals that received TMS compared to those that received sham
TMS. (A) Schematic outline of the five areas used to count huDPSCs in rat brain sections: IU, ipsilateral upper; IL, ipsilateral lower; CU, contralateral upper; CL,
contralateral lower; and MID, midline. (B) The average number of huDPSCs counted in five areas of 8 µm rat brain sections. n = 4–13 ± SEM, ∗ANOVA p = 0.0572,
t-test, p = 0.0469.
the total number of GFP expressing DPSC from all five sections
in animals treated with real TMS0.2 Hz or TMSsham. The findings
from analysis of GFP expressing DPSC in brain sections showed
animals that received an injection of DPSC followed by TMS
had significantly less surviving DPSC compared to animals that
received an injection of DPSC but received sham stimulation,
p = 0.0469 t-test (Figure 2B).
Decreased Trans-hemispheric Migration of
Implanted DPSC in TMS Treated Brains
Migration of the implanted DPSC from their injection site
across the brain hemispheres was investigated. GFP expressing
DPSC were counted in five areas as shown in Figure 2A.
Ipsilateral (indicating the hemisphere of injection) upper and
lower, contralateral upper and lower and a position in themidline
including the corpus collosum. Migration of DPSC was seen
in animals that received TMSsham from the site of injection to
the contralateral hemisphere. Half of the surviving DPSC from
the TMS0.2 Hz group were found in the same hemisphere of
implantation. Animals that received TMSsham were seen to have
a lower percentage of implanted DPSC in the hemisphere of
implantation compared to the contralateral side and the midline.
It appeared that TMS0.2 Hz significantly inhibited migration of
the DPSC to the contralateral hemisphere, p = 0.0458 (t-test;
Figure 3).
Implanted DPSC Co-localize with Neural
Stem Cell Marker Nestin
The surviving implanted DPSC were assessed for their
differentiation potential in vivo using immunohistochemistry.
Co-localization of GFP and antibodies against βIII-tubulin,
GFAP and nestin were used to identify implanted DPSC
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FIGURE 3 | Migration of implanted huDPSCs is decreased by TMS. Brain sections of rats treated with DPSCs + TMS show less migration from the side of
injections (ipsilateral hemisphere) to the contralateral hemisphere. Data is expressed as mean ± SEM, ∗p = 0.0458 t-test, l∼p = 0.0229 t-test.
that had differentiated into neurons, astrocytes, or had
maintained a progenitor-like phenotype, respectively. In
our previous study, GFP transduced human DPSC implanted
into the rodent brain following stroke (Leong et al., 2012)
expressed immunocytochemical markers consistent with
differentiation into astrocytes and neurons. In contrast, we
found no co-localization of GFP implanted human DPSC
with βIII-tubulin, mature neuronal marker NeuN or astrocytic
marker GFAP in eight brains that were examined (data not
shown). Instead, all surviving DPSC in the TMS0.2 Hz treated
group co-localized with nestin, a neural stem cell marker. This
result would suggest that less mature DPSC survived TMS0.2 Hz
treatment and that TMS0.2 Hz selected for a progenitor-like cell
from the total DPSC population that was implanted (Figure 4).
Implanted DPSC Express Cell Death
Marker Caspase-3
Due to the decreased number of implanted DPSC found in
TMS0.2 Hz treated animals, we investigated whether the surviving
cells expressed an apoptotic marker and destined for cell death.
Caspase-3 is one of the key executioners of apoptosis as it is
either partially or totally responsible for the proteolytic cleavage
of many key proteins (Fernandes-Alnemri et al., 1994). In
animals which had DPSC implanted and TMS0.2 Hz, implanted
cells (between 80–90% of DPSC) were seen to co-localize with
the Caspase-3 marker (Figure 5). This suggests that TMS or a
by-product following TMS caused activation of the Caspase-3
apoptotic pathway that resulted in reduced survival of implanted
DPSC. Caspase-3 staining was carried out on both TMS0.2 Hz
treated and TMSsham animals, with TMSsham animals showing
no Caspase-3 co-localization in implanted human DPSC, and
no Caspase-3 expression in the sub ventricular zone (data not
shown). This suggests Caspase-3 expression was localized to the
implanted human DPSC population.
Up-Regulation of Glutamate Decreases
DPSC Proliferation
We hypothesized that DPSC loss may have resulted from
glutaminergic toxicity resulting from TMS. An in vitro study of
the effect of glutamate on DPSC was carried out using levels of
glutamate calculated from data published by Zangen and Hyodo
(2002) which showed upregulation of glutamate to levels 75%
of normal physiological levels following TMS. This level was
determined in our in vitro study we exposed DPSC to increasing
levels of glutamate for 15min, 24 h or 15min/h for 6 h. All in vitro
tests showed high levels of glutamate 75%-100% significantly
decreased the number of DPSC seen at 24 h (one-way ANOVA;
Figure 6). Overall we found that 24 h after the initial incubation,
DPSC cell proliferation decreased or that no DPSC survived
varied glutamate level exposure.
DISCUSSION
This exploratory study was designed to investigate the potential
of TMS as a complementary therapy following the intracerebral
transplantation of stem cells into the mammalian brain.
We investigated whole brain TMS following human DPSC
implantation in a rodent brain, rather than focal stimulation
(localized to a specific brain area) to assess the global effect
of TMS following the delivery of human DPSC. We found
that significantly less transplanted DPSC survived in the rodent
brains following five sessions of TMS stimulation at an intensity
of 60% MSO over the course of 2 weeks (TMS0.2 Hz) compared
with TMSsham controls. Although the TMSsham control used
in this study is a clinically acceptable control in a human
study, there may have been a low level of stimulation to the
rodent brain as a result of the coil being orientated on a
90◦ angle, which may have provided a beneficial environment
for implanted DPSC survival. Secondly, the surviving cells
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FIGURE 4 | Implanted huDPSCs co-localize with neural stem cell marker nestin in animals treated with TMS(0.2 Hz). TMS treated brain sections stained for
(A) Green fluorescent protein (GFP) expressing huDPSCs (Green) and (B) Neural stem cell marker nestin (Red). (C) Merged image shows all GFP expressing
huDPSCs co-localize with nestin. Scale bar represents 25 µm in each panel.
FIGURE 5 | Implanted huDPSCs co-localize with cell death marker Caspase-3 in animals treated with TMS(0.2 Hz). TMS treated brain sections stained for
DAPI (blue) (A) Caspase-3 expressing cells (red) and (B) GFP expressing implanted huDPSCs (green). (C) Merged image shows GFP expressing huDPSCs
co-localize with Caspase-3. Scale bar represents 20 µm in each panel.
from the TMSsham group predominantly remained in the
injected cerebral hemisphere and did not migrate to the
contralateral hemisphere. This is a somewhat surprising and
unexpected finding. We have previously shown, that DPSC
when transplanted into the rodent brain following stroke,
migrated to the site of infarction, however, we also observed
migration of DPSC to the contralateral non-stroke cerebral
hemisphere (Leong et al., 2012). In the stroke model, stem cells
are chemo-attracted to the site of the infarction by cytokines
with one molecular pathway being CXCR4/CXCL-12 (SDF-1)
signaling (Arthur et al., 2009). However, in this particular study
there was no infarct, so the molecular mechanism whereby
DPSC migrated throughout the rodent brain into both cerebral
hemispheres is unclear. We can only hypothesize from our
current experiments that our TMS0.2 Hz paradigm does not
allow for migration of implanted DPSC throughout the rodent
brain.
Investigation of the differentiation phenotype of implanted
DPSC demonstrated that implanted GFP-expressing DPSC
treated with TMS predominantly expressed the neural progenitor
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FIGURE 6 | High levels of glutamate decrease huDPSC proliferation.
Cell proliferation assays carried out with increased levels of glutamate from
baseline levels show significantly decreased huDPSC proliferation 24 h after
incubation with glutamate for (A) 15 min ∗p = 0.003, l∼p = 0.0023, (B) 24 h
ANOVA p < 0.0001 and (C) Incubation for 15 min every hour for 6 h ANOVA
p = 0.0031.
cell marker nestin. This may suggest that TMS selected for
a neural-type of progenitor cell within the DPSC population.
In the sham controls we found neural antigen expressing
GFP cells originally derived from implanted DPSC but were
unable to find any such neural cells following TMSsham.
Our immunohistochemical examination of implanted DPSC
showed no neural markers (βIII-tubulin, GFAP or NeuN) were
co-localized with the implanted DPSC in TMS0.2 Hz treated
animals.
As there were significantly less (50% decrease) implanted
cells seen in the TMS0.2 Hz treated brains we investigated the
unexpected idea that TMS0.2 Hz may have led to death of DPSC.
This was investigated via Caspase-3 immunohistochemistry. We
thus found a large proportion of surviving DPSC co-localized
with the Caspase-3 apoptotic marker. To ensure that the
endogenous neural stem cells (in the sub-ventricular zone, SVZ)
were not affected in a similar manner by TMS0.2 Hz treatment we
investigated Caspase-3 expression by this stem cell population
and did not find any co-localization at the sub ventricular zone
in the rodent brain. Therefore TMS0.2 Hz treatment appeared
to be selectively detrimental to exogenously implanted stem
cells and not the endogenous stem cell population. The finding
that the majority of surviving DPSC expressed Caspase-3
may be explained as these cells were also destined to die
and join the majority of their counterparts. While the study
presented in this paper looked at Caspase-3 expression in the
SVZ to ensure no endogenous neural stem cell was caused
by TMS, a recent study by Abbasnia et al. (2015) showed
following 1 week of rTMS at a low frequency (1 Hz) neural
cells/progenitor cells derived from the SVZ of treated mouse
brains, proliferation as measured by neurosphere formation was
increased compared to cells derived from mice that received
high frequency (30 Hz) rTMS for 1 week (Abbasnia et al.,
2015).
We suggest a potential explanation for the detrimental
effect of TMS0.2 Hz treatment on DPSC survival may be due
to increased glutamate levels in the brain parenchyma. It has
previously been shown by Zangen and Hyodo (2002) that there
is an up-regulation of glutamate during TMS and high levels of
glutamate are cytotoxic. The study conducted by Zangen and
Hyodo (2002) used a different TMS paradigm than that used
in this study of 98% MSO at a frequency of 2 Hz, however,
this is one of the only studies to our knowledge to measure
glutamate levels in the rodent brain during TMS. Ideally, the
current study would have benefited from conducting a similar
study to that of Zangen and Hyodo (2002), however as it is an
exploratory study, this was not able to be completed. An in vitro
study completed, showed high levels of glutamate significantly
decreased DPSC proliferation and survival. This may be the case
in vivo.
Previous work carried out from this laboratory, in a rodent
stroke model where the same population of human DPSC were
injected 24 h post-stroke found only 2.3% of implanted DPSC
survived at 4 weeks. It is known following ischemic stroke that
there is an up-regulation of glutamate, which may support our
suggestion that DPSC death may be due to increased levels of
glutamate in the brain (Dirnagl et al., 1999; Leong et al., 2012).
There are a number of study limitations, which were a
result of this study being the first of its kind to explore a
complementary therapy of TMS and stem cell implantation.
One such limitation was that we only investigated the effect
of one set of TMS parameters. At the time of data collection
there were few studies available to provide a useful basis for
establishing the TMS intensity/stimulation frequency to achieve
optimal outcomes. Thus, in this exploratory study we used a
pragmatic approach and the highest frequency (0.2 Hz) and
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intensity (60% MSO) of TMS that was technically achievable for
the stimulation period, without the coil overheating. It is likely,
this intensity of stimulation resulted in significant activation
of glutaminergic neurons with elevated glutamate levels and
resultant toxicity to DPSC. It is possible that with lower stimulus
intensities TMS may result in more favorable modulations in
the cortical environment and less cell death of DPSC. Since
data collection, there have been a number of other studies
that have employed TMS in rodent models all with different
protocols and research questions (Gersner et al., 2011; Wang
et al., 2011; Tan et al., 2013), future experiments should focus on
optimizing the TMS protocol (including optimizing the protocol
design (continuous vis intermittent protocols), the intensity of
the stimulation and the frequency of the stimulation for DPSC
survival, based on the recently available evidence. Moreover,
anesthetizing the animals during the TMS stimulation may
have contributed to our results. Indeed Gersner et al. (2011),
demonstrated an increase in hippocampal BDNF after 10 days
of stimulation with similar intensity of stimulation in awake,
but not anesthetized animals. Interestingly, a lower frequency of
stimulation in their study resulted no increase of BDNF levels.
Taking these findings together with our own, there may be
a fine balance between providing an optimal environment for
DPSC implantation by promoting increases in BDNF, without
increasing glutamate, which may promote DPSC cell death. In
future studies, we would suggest that measurement of glutamate
levels in the brain during the TMS sessions via cannulation
of the brain would provide a better understanding of the
brain microenvironment and how this may affect implanted
DPSC.
We hypothesized that TMS stimulation following injection of
DPSC would provide an environment which would enhance the
survival and neural differentiation of the implanted stem cells.
Contrary to this hypothesis, our findings indicated that at the
intensity and frequency tested (60% MSO, 0.2 Hz), TMS did not
enhance transplanted DPSC survival and restricted migration of
the implanted DPSC to the contralateral hemisphere. These data
suggest that TMS may offer a novel complementary treatment
to restrict stem cells to the site of implantation where they
would be required for neuro-restoration following infarction.
However, this restriction of movement throughout the brain
parenchyma is at the expense of DPSC survival which is
the ultimate goal, therefore, further studies are required to
determine the optimal intensity of stimulation that can provide
a brain environment which enhances the survival, differentiation
and proliferation of implanted stem cells in the mammalian
brain.
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